Dr. Sandra Turcotte, PhD
Department of Chemistry and Biochemistry, Université de Moncton
Researcher in residence at Atlantic Cancer Research Institute
Research Chair, Canadian Cancer Society, NB
Exploiting synthetic lethality in kidney cancer for the development of anticancer therapy; miRNA profiling and target prediction in Renal Cell Carcinoma; Characterization of the role of VHL in autophagy
Fighting kidney cancer the von Hippel-Lindau way
Dr Sandra Turcotte is Assistant Professor at the Université de Moncton and researcher in residence at the Atlantic Cancer Research Institute. She completed her PhD in Biochemistry at the Université du Québec à Montréal and Post-doctoral Fellowships at Stanford University in California and at the CRCHUM in Montreal.
Her research focus on developing new targeted therapy for kidney cancer. Her studies identify a small molecule that kills renal cancer cells and spare normal cells. Her laboratory uses a variety of methods in cell and molecular biology to study the role of autophagy in kidney cancer. Dr Turcotte hold a Canadian Cancer Society Research Chair in New Brunswick and is a KRESCENT New Investigator awardee.